ALK and non-small cell lung carcinoma: The ALINA trial (NCT03456076) is comparing 24 months of adjuvant alectinib with the standard of care (4 cycles of chemotherapy) in patients with stage IB–IIIA resected ALK-rearranged NSCLC.